Immunotherapy Outcomes in Individuals With Non-Small Cell Lung Cancer and Poor Performance Status.
Rajwanth VeluswamyLiangyuan HuCardinale B SmithJiayi JiXiaoliang WangJuan WisniveskyJose MorilloMinal S KalePublished in: JNCI cancer spectrum (2022)
Among a highly representative sample of patients with advanced NSCLC and poor PS, our findings suggest that immunotherapy may provide an important survival benefit in individuals with high PD-(L)1-expressing tumors and in conjunction with chemotherapy in tumors with low PD-(L)1 expression.